Three-hydroxy-3methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) reduce coronary events and death in both primary and secondary prevention trials. In these trials benefit did not appear for years after randomization[1••,2,3]. It is noteworthy that these trials did not include patients with recent myocardial infarctions or unstable angina. It is well known that mortality and recurrent ischemic events rates are the highest in the early period after acute coronary syndromes[4,5,6]. Favorable physiologic effects of statins have been described within a few weeks of exposure to the statin in a number of experimental studies[7–10]. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study[11]was designed to bridge the gap between primary and secondary prevention trials and specifically included patients with unstable angina or non-ST elevation myocardial infarction.